Orgentec specializes in diagnostic assays that are used by laboratories in more than 100 countries. The company develops and produces tests, primarily enzyme-linked immunosorbent assays (ELISA), that help diagnose the increasing number of people impacted by autoimmune disorders and infectious diseases. It’s one of the only companies in its field to offer a proprietary automated instrument – the Alegria – and associated test kits that enable labs to complete multiple assays and deliver faster results than traditional tests. Based in Germany, Orgentec has a strong position in Europe. The company also has a significant foothold in the United States with Corgenix, a medical diagnostics business that specializes in the development, tech transfer, registration, manufacturing, and commercialization of specialty diagnostics tests. Corgenix is a full-service partner to diagnostic and pharmaceutical companies in developing tests on their preferred platform to support their research, clinical trial testing, and routine clinical testing needs. Water Street is working with Orgentec and Corgenix to expand their businesses into new areas of testing and geographic markets.
President & CEOWork with us
Gary Winer was appointed president and CEO of Orgentec in 2019. He is a highly accomplished executive who has led numerous global diagnostic and pharmaceutical businesses over the course of his nearly 30-year career. Gary has made significant leadership impact and increased revenues for such Fortune 100 companies as AbbVie, Abbott Laboratories and Pfizer. He has spearheaded successful launches and growth of blockbuster product lines, namely Celebrex and Humira, across the United States, Latin America, Asia and Japan. During his nearly 10 years with Abbott, Gary managed the company’s diagnostic business in the U.S., Canada and Latin America before being promoted to lead Abbott Japan, the company’s largest affiliate outside the U.S. In addition to driving strong growth, he was instrumental in helping the business to achieve “Best Places to Work” recognition three years in a row. Gary continued in this leadership role after planning and completing the separation of Abbott’s pharmaceutical business in Japan to form AbbVie. Gary received his bachelor’s degree in finance from California State University and his master’s in business administration from Northwestern University’s Kellogg School of Management.